Drug Combo Boosts Lung Cancer Survival Free

Treatment with lurbinectedin (Zepzelca; Jazz Pharmaceuticals) and atezolizumab (Tecentriq; Genentech) improved overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC) in the phase III IMforte trial. Median OS among the 242 patients with ES-SCLC who received the alkylating agent lurbinectedin, which damages cancer cell’s DNA, and the anti–PD-L1 mAb, respectively,  was 13.2 months, compared with 10.6 months in the 241 patients who received atezolizumab alone. Progression-free survival in the two groups was 5.4 months and 2.1 months, respectively. The results were presented during a press conference in advance of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, where they will be presented more formally.